UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1113P Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America

Annals of oncology, 2021-09, Vol.32, p.S917-S917

2021

Volltextzugriff (PDF)

1148MO A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study

Annals of oncology, 2024-09, Vol.35, p.S753-S753

2024

Volltextzugriff (PDF)

1308OActivity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

[ 177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.LBA588-LBA588

2024

Volltextzugriff (PDF)

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

The Lancet (British edition), 2024-06, Vol.403 (10446), p.2807-2817

2024

Volltextzugriff (PDF)

211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study

Annals of oncology, 2024-06, Vol.35, p.S92-S93

2024

Volltextzugriff (PDF)

551. Antibiotic Use Among Surgical Patients in the Neonatal Intensive Care Unit (NICU): The NO-More-AntibioticS and Resistance in Surgery (NO-MAS-R-S) Study

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

European journal of cancer (1990), 2015-09, Vol.51, p.S709-S710

2015

Volltextzugriff (PDF)

6571 POSTER Impact of Prior Somatostatin Analog (SSA) Use on PFS in the Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Patients With Advanced Neuroendocrine Tumours (RADIANT-2)

European journal of cancer (1990), 2011, Vol.47, p.S462-S463

2011

Volltextzugriff (PDF)

92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 Study

Radiotherapy and oncology, 2022-09, Vol.174, p.S40-S41

2022

Volltextzugriff (PDF)

Abstract 6694: Highly selective anti-CCR8 antibody-mediated depletion of regulatory T cells leads to potent antitumor activity alone and in combination with anti-PD-1 in preclinical models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6694-6694

2020

Volltextzugriff (PDF)

Accessing the Spectral Function in a Current-Carrying Device

Physical review letters, 2020-12, Vol.125 (23), p.236403-236403, Article 236403

2020

Volltextzugriff (PDF)

ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA

Endocrine Abstracts, 2023-02

2023

Volltextzugriff (PDF)

ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177 Lu somatostatin analogue (SSA) therapy: Initial safety analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4132-4132

2023

Volltextzugriff (PDF)

Activating Effects of Phenolics from Apache Red Zea mays L. on Free Fatty Acid Receptor 1 and Glucokinase Evaluated with a Dual Culture System with Epithelial, Pancreatic, and Liver Cells

Journal of agricultural and food chemistry, 2019-08, Vol.67 (33), p.9148-9159

2019

Volltextzugriff (PDF)

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Annals of oncology, 2018-10, Vol.29, p.viii467-viii468

2018

Volltextzugriff (PDF)

Adrenal Cortical Carcinoma Associated With Lynch Syndrome: A Case Report and Review of Literature

Journal of the Endocrine Society, 2019, Vol.3 (4), p.784-790

2019

Volltextzugriff (PDF)

Adrenal Cortical Carcinoma Associated With Lynch Syndrome: A Case Report and Review of Literature

Journal of the Endocrine Society, 2019-04, Vol.3 (4), p.784-790

2019

Volltextzugriff (PDF)

Advances in Materials Science for Environmental and Energy Technologies II

Josef Matyáš, Tatsuki Ohji, Xingbo Liu, M. Parans Paranthaman, Ram Devanathan, Kevin M. Fox, Mrityunjay Singh, Winnie Wong-Ng

1, 2013

Volltextzugriff (PDF)

Advances in Statistical Feature Selection

Advances in Pattern Recognition — ICAPR 2001, p.427-436

Volltextzugriff (PDF)

Algorithmic Advances and Applications from RECOMB 2017

Cell systems, 2017-09, Vol.5 (3), p.176-186

2017

Volltextzugriff (PDF)

Amino Acid: Its Dual Role as Nutrient and Scavenger of Free Radicals in Soil

Sustainability, 2017-08, Vol.9 (8), p.1402

2017

Volltextzugriff (PDF)

Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness

Health technology assessment (Winchester, England), 2017-09, Vol.21 (49), p.1-56

2017

Volltextzugriff (PDF)

1 – 25 von 350

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(269)
Mit Volltextzugriff
(310)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(349)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(213)
Life Sciences & Biomedicine
(112)
Technology
(82)
Physical Sciences
(63)
Humans
(57)
Materials Science
(36)
Chemistry
(32)
Female
(32)
Physics
(32)
Materials Science, Multidisciplinary
(31)
Male
(28)
Biochemistry & Molecular Biology
(24)
Adult
(22)
Telecommunications
(21)
Chemistry, Multidisciplinary
(20)
Middle Aged
(19)
Nanoparticles
(19)
Science & Technology - Other Topics
(18)
Engineering
(17)
Oncology
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

1113P Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America

1148MO A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study

1308OActivity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

[ 177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

177LuLu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study

551. Antibiotic Use Among Surgical Patients in the Neonatal Intensive Care Unit (NICU): The NO-More-AntibioticS and Resistance in Surgery (NO-MAS-R-S) Study

5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

6571 POSTER Impact of Prior Somatostatin Analog (SSA) Use on PFS in the Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Patients With Advanced Neuroendocrine Tumours (RADIANT-2)

92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 Study

Abstract 6694: Highly selective anti-CCR8 antibody-mediated depletion of regulatory T cells leads to potent antitumor activity alone and in combination with anti-PD-1 in preclinical models

Accessing the Spectral Function in a Current-Carrying Device

ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA

ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177 Lu somatostatin analogue (SSA) therapy: Initial safety analysis

Activating Effects of Phenolics from Apache Red Zea mays L. on Free Fatty Acid Receptor 1 and Glucokinase Evaluated with a Dual Culture System with Epithelial, Pancreatic, and Liver Cells

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Adrenal Cortical Carcinoma Associated With Lynch Syndrome: A Case Report and Review of Literature

Adrenal Cortical Carcinoma Associated With Lynch Syndrome: A Case Report and Review of Literature

Advances in Materials Science for Environmental and Energy Technologies II

Advances in Statistical Feature Selection

Algorithmic Advances and Applications from RECOMB 2017

Amino Acid: Its Dual Role as Nutrient and Scavenger of Free Radicals in Soil

Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness

Suchergebnisse filtern